Developer docs
API playgroundTry for free, no card

Search company profiles

Boston Genetics

Full company profile

uuid00323tz

Namestring
Boston Genetics
Websiteurl
bostongen.com
Company typeenum
Private
Founded yearint
2019
Short descriptiontext

Boston Genetics (operating via Genomenon) provides curated genomic intelligence — including the Mastermind database of 26M+ variants and CKB cancer knowledgebase — plus expert clinical diagnostic services to biopharma firms and clinical laboratories.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
genomic intelligence platform, variant interpretation software, clinical diagnostic services, cancer knowledgebase, real-world evidence genomics
Industry3 codes
PRIMARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
NAICS code2 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Genomic Intelligence Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Software Subscriptions
TypeSubscription Recurring
Description

Access to Mastermind genomic database and CKB platform for variant interpretation, likely offered as subscription-based access

genomenon.com
2Clinical Diagnostic Services
TypeProfessional Services
Description

Expert curation and interpretation services offered as tailored solutions for clinical labs, acting as an extension of client's team

genomenon.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Enterprise/Bespoke pricing
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Quote-based pricing not publicly disclosed

genomenon.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Boston Genetics is a curated data solutions provider for large genomic laboratories, offering a genomic intelligence platform that includes the Mastermind database (covering 26M+ variants) and the Cancer Knowledgebase (CKB) for variant interpretation. The company delivers expert clinical diagnostic services, real-world evidence solutions, and curated genomic data to biopharma firms and clinical labs, helping them accelerate variant curation, reduce turnaround times, and improve diagnostic accuracy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Reduced a 1-year patient backlog in 5.5 months
+5 more records
Product overview1 text field

Genomenon offers a unified genomic intelligence platform consisting of Mastermind (core genomic database for germline variants), CKB (Cancer Knowledgebase for somatic variants), and Clinical Diagnostic Services. These products work together to provide comprehensive variant interpretation through literature-driven evidence, connecting genomic data to clinical decisions for both biopharma and clinical lab customers.

Product and service6 records
1Mastermind
CategoryCore product
Description

Genomic intelligence platform providing literature-driven variant interpretation for germline variants, offering access to article information on more than 26 million variants with curated germline variant content for clinical labs and biopharma.

2CKB (Cancer Knowledgebase)
CategoryCore product
Description

Cancer variant knowledgebase used to interpret cancer variants, connecting them to therapies and clinical trials for somatic variant interpretation in clinical labs and biopharma.

3Clinical Diagnostic Services
CategoryService offering
Description

Expert clinical services including workflow and process optimization, variant/gene curation and interpretation, data accuracy and platform improvements, regulatory compliance, and organizational development for clinical diagnostic laboratories.

4Real World Evidence
CategoryService offering
Description

Literature-driven real-world evidence platform designed for biopharma to accelerate development, expand disease insights, optimize clinical trials, and bring precision therapies to patients.

5Genetic Disease Sponsorship
CategoryService offering
Description

Program providing clinicians and researchers open access to curated genetic evidence to reduce diagnostic barriers and advance scientific understanding.

6Genomic Data
CategoryData product
Description

Expansive, constantly updated database of curated genomic information for variant analysis and interpretation.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Invitae (now operating with ArcherDX/PDT) provides clinical genetic testing and interpretation software for rare disease, oncology, and reproductive health — a broad incumbent serving clinical labs and biopharma with overlapping variant interpretation and curation capabilities.

2PierianDx
TypeDirect peer
Description

PierianDx (now part of the Fabric Genomics / GeneDx ecosystem) provides a clinical genomics platform for variant interpretation, tertiary analysis, and clinical reporting — a direct peer in lab-facing genomic interpretation software.

3Tempus Labs
TypeEmerging player
Description

Tempus combines molecular profiling, real-world clinical-genomic data, and AI tools for precision medicine, serving both biopharma and providers — an emerging player with overlapping biopharma RWE and clinical genomics use cases, though with a broader data and diagnostics scope than Boston Genetics.

TypeBroad incumbent
Description

GeneDx is a clinical genetics laboratory offering exome/genome sequencing and interpretation services to clinicians and biopharma — a broad incumbent that competes with Boston Genetics' clinical lab services arm and has now absorbed Fabric Genomics as its interpretation platform.

TypeDirect peer
Description

Congenica delivers a clinical genomic analysis platform for rare disease and somatic cancer interpretation used by clinical labs and biopharma — directly comparable in offering curated variant databases, clinical decision support, and laboratory workflow tools.

TypeBroad incumbent
Description

Illumina offers BaseSpace Variant Interpreter and related tertiary analysis tools bundled with its sequencing instruments — a broad incumbent with overlapping interpretation capabilities, often paired with sequencing-platform lock-in rather than sold as a standalone database.

TypeDirect peer
Description

Molecular Health provides genomic clinical decision support software for oncology and rare disease, connecting variants to therapies and clinical evidence — a direct peer in literature-driven, therapy-linking variant interpretation for biopharma and clinical labs.

TypeDirect peer
Description

SOPHiA Genetics offers an AI-driven platform for genomic and multimodal data analysis used by clinical labs and biopharma for variant interpretation and clinical decision support — a directly comparable genomic intelligence and interpretation play targeting the same customer base.

TypeDirect peer
Description

Fabric Genomics provides AI-powered clinical genomic interpretation software for rare disease and hereditary cancer, serving clinical labs and health systems — a direct competitor in the clinical variant interpretation and curation market Boston Genetics addresses.

TypeBroad incumbent
Description

Qiagen's Digital Insights business (Ingenuity, QCI, HGMD) provides variant interpretation and knowledge bases used by clinical labs and biopharma — a broad incumbent that competes head-to-head with Mastermind for variant knowledge and clinical decision support, though as part of a much larger sample-to-insight portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Boston Genetics

Genomic Intelligence Softwarebostongen.com

Boston Genetics (operating via Genomenon) provides curated genomic intelligence — including the Mastermind database of 26M+ variants and CKB cancer knowledgebase — plus expert clinical diagnostic services to biopharma firms and clinical laboratories.

Boston Genetics firmographics

Firmographics
Name
Boston Genetics
Website
https://bostongen.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Boston Genetics (operating via Genomenon) provides curated genomic intelligence — including the Mastermind database of 26M+ variants and CKB cancer knowledgebase — plus expert clinical diagnostic services to biopharma firms and clinical laboratories.
Ownership category
akta.pro rank

Boston Genetics industry classification

Industry
Product category
Genomic Intelligence Software
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories

Keywords

  • Genomic intelligence platform
  • Variant interpretation software
  • Clinical diagnostic services
  • Cancer knowledgebase
  • Real-world evidence genomics

Where Boston Genetics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

Boston Genetics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Software Subscriptions: Access to Mastermind genomic database and CKB platform for variant interpretation, likely offered as subscription-based access
  2. Clinical Diagnostic Services: Expert curation and interpretation services offered as tailored solutions for clinical labs, acting as an extension of client's team

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractEnterprise/Bespoke pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Boston Genetics product offering

Product offering

Core offering

Boston Genetics is a curated data solutions provider for large genomic laboratories, offering a genomic intelligence platform that includes the Mastermind database (covering 26M+ variants) and the Cancer Knowledgebase (CKB) for variant interpretation. The company delivers expert clinical diagnostic services, real-world evidence solutions, and curated genomic data to biopharma firms and clinical labs, helping them accelerate variant curation, reduce turnaround times, and improve diagnostic accuracy.

Product overview

Genomenon offers a unified genomic intelligence platform consisting of Mastermind (core genomic database for germline variants), CKB (Cancer Knowledgebase for somatic variants), and Clinical Diagnostic Services. These products work together to provide comprehensive variant interpretation through literature-driven evidence, connecting genomic data to clinical decisions for both biopharma and clinical lab customers.

Differentiator

Problem solved

Functional benefit

Products and services

  • Mastermind Genomic intelligence platform providing literature-driven variant interpretation for germline variants, offering access to article information on more than 26 million variants with curated germline variant content for clinical labs and biopharma.
  • CKB (Cancer Knowledgebase) Cancer variant knowledgebase used to interpret cancer variants, connecting them to therapies and clinical trials for somatic variant interpretation in clinical labs and biopharma.
  • Clinical Diagnostic Services Expert clinical services including workflow and process optimization, variant/gene curation and interpretation, data accuracy and platform improvements, regulatory compliance, and organizational development for clinical diagnostic laboratories.
  • Real World Evidence Literature-driven real-world evidence platform designed for biopharma to accelerate development, expand disease insights, optimize clinical trials, and bring precision therapies to patients.
  • Genetic Disease Sponsorship Program providing clinicians and researchers open access to curated genetic evidence to reduce diagnostic barriers and advance scientific understanding.
  • Genomic Data Expansive, constantly updated database of curated genomic information for variant analysis and interpretation.

Quantifiable outcome

  • Reduced a 1-year patient backlog in 5.5 months
  • +5 more outcomes

Companies that use Boston Genetics

Customer profile

Segments2 records

Ideal customer profiles2 records

Boston Genetics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Boston Genetics partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves5 records

Expansion highlights5 records

Boston Genetics competitors and assessment

Company assessment

Broad incumbents

  • Invitae: Invitae (now operating with ArcherDX/PDT) provides clinical genetic testing and interpretation software for rare disease, oncology, and reproductive health — a broad incumbent serving clinical labs and biopharma with overlapping variant interpretation and curation capabilities.
  • GeneDx: GeneDx is a clinical genetics laboratory offering exome/genome sequencing and interpretation services to clinicians and biopharma — a broad incumbent that competes with Boston Genetics' clinical lab services arm and has now absorbed Fabric Genomics as its interpretation platform.
  • Illumina (Connected Insights / BaseSpace): Illumina offers BaseSpace Variant Interpreter and related tertiary analysis tools bundled with its sequencing instruments — a broad incumbent with overlapping interpretation capabilities, often paired with sequencing-platform lock-in rather than sold as a standalone database.
  • Qiagen Digital Insights: Qiagen's Digital Insights business (Ingenuity, QCI, HGMD) provides variant interpretation and knowledge bases used by clinical labs and biopharma — a broad incumbent that competes head-to-head with Mastermind for variant knowledge and clinical decision support, though as part of a much larger sample-to-insight portfolio.

Direct peers

  • PierianDx: PierianDx (now part of the Fabric Genomics / GeneDx ecosystem) provides a clinical genomics platform for variant interpretation, tertiary analysis, and clinical reporting — a direct peer in lab-facing genomic interpretation software.
  • Congenica: Congenica delivers a clinical genomic analysis platform for rare disease and somatic cancer interpretation used by clinical labs and biopharma — directly comparable in offering curated variant databases, clinical decision support, and laboratory workflow tools.
  • Molecular Health: Molecular Health provides genomic clinical decision support software for oncology and rare disease, connecting variants to therapies and clinical evidence — a direct peer in literature-driven, therapy-linking variant interpretation for biopharma and clinical labs.
  • SOPHiA Genetics: SOPHiA Genetics offers an AI-driven platform for genomic and multimodal data analysis used by clinical labs and biopharma for variant interpretation and clinical decision support — a directly comparable genomic intelligence and interpretation play targeting the same customer base.
  • Fabric Genomics (GeneDx): Fabric Genomics provides AI-powered clinical genomic interpretation software for rare disease and hereditary cancer, serving clinical labs and health systems — a direct competitor in the clinical variant interpretation and curation market Boston Genetics addresses.

Emerging players

  • Tempus Labs: Tempus combines molecular profiling, real-world clinical-genomic data, and AI tools for precision medicine, serving both biopharma and providers — an emerging player with overlapping biopharma RWE and clinical genomics use cases, though with a broader data and diagnostics scope than Boston Genetics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Boston Genetics social profiles

Digital presence

Boston Genetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Boston Genetics leadership team

Management profile

Number of profiles

Boston Genetics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Boston Genetics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Boston Genetics

What does Boston Genetics do?

Boston Genetics is a curated data solutions provider for large genomic laboratories, offering a genomic intelligence platform that includes the Mastermind database (covering 26M+ variants) and the Cancer Knowledgebase (CKB) for variant interpretation. The company delivers expert clinical diagnostic services, real-world evidence solutions, and curated genomic data to biopharma firms and clinical labs, helping them accelerate variant curation, reduce turnaround times, and improve diagnostic accuracy.

Is Boston Genetics a public or private company?

Boston Genetics is a private company. It is classified as unknown and is currently operating.

When was Boston Genetics founded?

Boston Genetics was founded in 2019. It employs 11 to 50 people.

Where is Boston Genetics based?

Boston Genetics is headquartered in Cambridge, United States, in the North America region.

How does Boston Genetics make money?

Two revenue lines are on record. Software Subscriptions are the primary driver. The others are clinical Diagnostic Services.

Who are Boston Genetics's main competitors?

Broad incumbents on record are Invitae, GeneDx, Illumina (Connected Insights / BaseSpace) and Qiagen Digital Insights. Direct peers are PierianDx, Congenica, Molecular Health, SOPHiA Genetics and Fabric Genomics (GeneDx). Tempus Labs is listed as an emerging player.

Does Boston Genetics have an API?

No public API is recorded for Boston Genetics.

What industry is Boston Genetics in?

Boston Genetics's product category is Genomic Intelligence Software. Its primary akta.pro industry code is HLAGAEAD, Genomics & Molecular Diagnostics (Trial Support), with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comCompetitive Landscape: Key Market Leaders and New Entrants in the Somatic Genetic Testing SectorThe Business Research Company released a market report projecting the somatic genetic testing sector will reach $14.92 billion by 2030, driven by next-generation sequencing and precision medicine adoption. The article highlights strategic activities including Genomenon Inc.'s acquisition of Boston Genetics Inc. to enhance genomic interpretation capabilities and Strand Life Sciences' launch of a new liquid biopsy test in India.openPR.comOverview of Segmentation, Market Dynamics, and Competitive Landscape in the Pharmacogenomics MarketThe pharmacogenomics market is projected to reach $15.98 billion by 2030, growing at a 10.2% CAGR, driven by precision medicine funding, AI-powered genomic analysis, and expanded applications in oncology and cardiology. In June 2023, Genomenon acquired Boston Genetics to combine its AI-driven genomic platform with Boston Genetics' genetic science expertise for clinical diagnostics and pharmaceutical development. In December 2024, PGxAI launched its Sirius AI model, which personalizes drug selection and dosage based on a patient's genome, covering 730 drugs and 40 pharmacogenes.GenomenonGenomenon and Boston Genetics Join Forces to Curate the Human GenomeGenomenon announced the acquisition of Boston Genetics, enhancing its capabilities in genomic interpretation and curation. The acquisition will double Genomenon's workforce and establish a new data service arm, improving offerings for clinical diagnostics and pharmaceutical development. This move aligns with the growing need for comprehensive genomic curation in precision medicine.PrwebGenomenon Acquires Boston Genetics to Accelerate Curation of Human GenomeGenomenon Inc. has acquired Boston Genetics to expand its genomic interpretation capabilities and accelerate the curation of the human genome. This acquisition combines Genomenon's AI-powered platform with Boston Genetics' scientific expertise, creating a new data service arm for clinical diagnostic and pharmaceutical clients.